Evidence desk · Supplement
Fish oil / omega-3
The verdict
Real, useful, and badly oversold. The long-chain omega-3s EPA and DHA reliably lower triglycerides, and there's a decent signal for mood and a few specific conditions. But the headline promise — fewer heart attacks from a daily fish-oil capsule — mostly failed in the big randomized trials. One high-dose prescription trial is positive, and it comes with an asterisk.
The cleanest dietary source is fatty fish, where the evidence is most consistent. For you specifically, your panel is already in range on a double-dose supplement — so the live question isn't whether to add more (the trials say higher doesn't help), it's whether you still need that second dose. See For you.
Before you read on
You can pay to measure your "omega-3 index" and push it higher with pills. Yet the large trials that handed people fish oil mostly found no reduction in heart attacks or deaths. So: is a higher index worth chasing — and what kind of number is the index in the first place?
The claims, sorted
Omega-3 is sold for a long list of things at very different doses. They don't share a verdict, so separate them before reading any single study.
| Claim | Best evidence | Holds up? |
|---|---|---|
| Lowers triglycerides | Dose-dependent RCTs (2–4 g/day) | Yes |
| Fewer CV events — everyday ~1 g pill | VITAL, ASCEND (large RCTs) | No — mostly null |
| Fewer CV events — high-dose Rx EPA | REDUCE-IT positive; STRENGTH null | Contested |
| Mood / depression | Meta-analyses, high-EPA formulas | Modest, real-ish |
| Plant omega-3 (ALA: flax, chia) | Poor conversion to EPA/DHA | Weak substitute |
| Higher omega-3 index = better outcomes | Observational; it's a surrogate | Unproven once replete |
The big trials mostly came back null
This is the part the supplement aisle skips. When researchers ran large randomized trials of everyday-dose fish oil against placebo and counted hard outcomes — heart attacks, strokes, deaths — the benefit largely vanished. VITAL (nearly 26,000 people, ~1 g/day) missed its primary cardiovascular endpoint. ASCEND (in people with diabetes) was null. The exception, REDUCE-IT, used a high dose (4 g/day) of purified EPA in statin-treated patients with high triglycerides and did cut events — but a near-identical high-dose trial, STRENGTH, found nothing.
The one positive trial, and its asterisk
REDUCE-IT is the study fish-oil marketing leans on, so it's worth knowing why careful readers don't treat it as settled. Two problems. First, replication failed: STRENGTH gave a similar high dose and found no benefit, which is exactly the kind of contradiction that should lower your confidence rather than letting you pick the winner. Second, REDUCE-IT used a mineral-oil placebo that may have slightly worsened the comparison group's markers — which would inflate the apparent benefit of the drug. Add a documented increase in atrial fibrillation at high doses, and the honest read is "promising in one specific high-risk group, not proven, not for everyone."
The index is a surrogate — that's the whole trick
The "omega-3 index" (the EPA+DHA share of your red-blood-cell membranes, target ~8%) is a real, validated biomarker — but it's a surrogate, not an outcome. A higher index is associated with lower risk in observational data, but the trials that actually raised people's index with supplements mostly didn't lower hard outcomes. So once you're in the healthy range, pushing the number higher is optimizing a proxy, not a result. Worth flagging the conflict, too: the most prominent index booster, Rhonda Patrick, has an undisclosed-as-commercial tie to the company selling the index test (see the Patrick scorecard) — to her credit, she reports the null trials honestly.
Food beats the pill
A pattern worth internalizing: the evidence for eating fish is more consistent than the evidence for fish-oil capsules. Whole fatty fish comes with complete protein and a food matrix the pills can't replicate, and dietary-fish studies tend to look better than supplement trials. Two cautions for capsules: ALA (plant omega-3 from flax/chia) converts to EPA/DHA poorly, so it's a weak substitute; and fish-oil softgels can oxidize (go rancid), so freshness and third-party testing matter. If you eat fish a couple of times a week, you likely need very little from a bottle.
By phase
Unlike most levers here, omega-3 barely shifts by phase — the call is "maintain" throughout. The reason it earns space at all is the two-for-one with dietary protein. Your specific call is in the For you section below.
Phase 1 · Aggressive cut (Zepbound)
Get it from the plate. Fatty fish (salmon, sardines, mackerel) does double duty on a cut: high-quality protein toward your 170 g floor and EPA+DHA in one food. That's the efficient move — no escalation, no extra capsule needed if you're already replete.
Phase 2 · Building muscle
Same call. Some evidence suggests omega-3 may modestly support muscle protein synthesis, but it's minor next to protein and training. Keep fish in the rotation; don't add a supplement expecting a muscle effect.
Phase 3 · Maintenance
Maintain. Keep your index in range with diet (or a modest supplement if fish intake drops). There's no phase where chasing a higher index pays off.
For you
From your actual omega-3 panel (you shared it). Good news first: you're in solid shape. Omega-6/omega-3 ratio 5.60 (favorable — lower is better, and 5.60 sits near the good end of the 4–14 band), omega-3 total 6.20% (comfortably in range, upper-middle of 2.40–9.20), omega-6 total 34.5% (in range). Not deficient, not over the top.
A measurement note · total ≠ index
Your Omega-3 Total is Function Health's roll-up of the major omega-3 fatty acids — EPA, DHA, and ALA (the plant one) — reported by weight. The famous "Omega-3 Index" with the ~8% target is a narrower, different test: EPA + DHA only, measured in red-blood-cell membranes. Different components and a different blood fraction — so the two aren't on the same scale, and your 6.2% should not be held against an 8% goal from a test you didn't take. Judge it against the range it shipped with, where you're comfortably in range.
The correction to my earlier draft: that good status isn't coming from food — you've been running a double dose of Sports Research omega-3 (roughly ~1.8 g EPA+DHA/day) for a few months. So the supplement is the active lever here, not a backstop. That reframes your question from "should I take fish oil?" to "do I need the full double dose to hold these numbers?"
My call — you're past "enough"; test whether the second dose earns its place
You're comfortably in range with a good ratio, and the trials are clear that pushing omega-3 higher doesn't lower hard outcomes. So there's no case to escalate, and no case to stop on health grounds either — you're fine. The genuinely useful move is to find out whether you need both softgels. Unlike most supplements on this desk, this is a clean n-of-1: the marker is measurable and the intervention is isolated. Drop to a single dose for ~3–4 months, then re-run this exact panel:
• Still in range, ratio still good → the second softgel wasn't buying you anything measurable. Keep the single dose, pocket the rest.
• Total drifts toward the low end / ratio climbs → the double dose was doing real work. Reinstate it. Now you know instead of guessing.
Two things unchanged. It's still not your lipid lever — ApoB 89 stays the cardiovascular target for diet and a possible statin chat with your doctor (see the protocol), and omega-3 won't move it (high-dose DHA can even nudge LDL-C up). And the atrial-fibrillation signal is a >4 g/day concern; your ~1.8 g sits well under it — so the reason to test a step-down is "unproven marginal benefit," not safety.
Profile used: 41, Phase 1 cut on Zepbound. Your omega-3 panel: ratio 5.60 (normal), omega-3 total 6.20% (in range), omega-6 total 34.5% (in range) — achieved while on a double dose of Sports Research omega-3 (~1.8 g EPA+DHA/day) for a few months. ApoB 89 ("watch") is the live lipid target; no high-triglyceride indication on record. Re-test after any dose change and I'll re-read it.
Recall check
- VITAL and ASCEND handed people fish oil and counted heart attacks. What did they find — and why does that matter more than an improved blood marker?
- REDUCE-IT was positive. Name the two reasons a careful reader still doesn't treat it as settled.
- The "omega-3 index" is a validated biomarker. So why isn't pushing it higher automatically a good idea?
- Why is "eat the salmon" a better default than "take the capsule" — and why does that fit your cut especially well?
Explain it back
In one sentence: if your omega-3 index is already optimal, why is "take more fish oil" the wrong move — and what number should get that attention instead?
Check it yourself
This verdict is just the toolkit applied. Re-derive it with surrogate vs hard outcomes (the index is the surrogate), the evidence ladder (one trial vs its failed replication), and is it strong enough to act? — then see where it sits in the protocol.
Sources · VITAL: marine n-3 & cardiovascular disease (NEJM, 2019) · REDUCE-IT: icosapent ethyl (NEJM, 2019) · STRENGTH: high-dose EPA/DHA, null (JAMA, 2020) · Cochrane review: omega-3 for cardiovascular prevention (2020). Evidence summaries, not medical advice — confirm anything that touches your medication or labs with your prescriber.